Skip to main content
SpringerLink
Log in

The evaluation of miR-1181 and miR-4314 as serum microRNA biomarkers for epithelial ovarian cancer diagnosis and prognosis

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Aim

Epithelial ovarian cancer (EOC) is the most ominous tumor of gynecological cancers due to its poor early detection rate and unfavorable prognosis. To date, there is no reliable screening method for the diagnosis of ovarian cancer at an early stage. MiRNAs are small non-coding RNA molecules, and their main function is to regulate gene expression. The present study compared the serum miR-1181 and miR-4314 levels in patients with EOC and healthy controls to measure the diagnostic and prognostic value as candidate biomarkers.

Materials and methods

We collected serum samples from a total of 135 participants (69 patients with EOC and 66 healthy controls). Relative expressions of miR-1181 and miR-4314 were measured by quantitative real-time polymerase chain reaction assay (qPCR).

Results

The present study revealed that both serum miR-1181 and miR-4314 levels in patients with EOC were significantly increased compared to healthy controls for each marker. In addition, there was a significant relationship between miR-1181 and miR-4314 overexpressions and the stage and prognosis of the disease. Finally, patients with high expression levels of miR-1181 and miR-4314 had significantly shorter survival rates than those with low expression levels.

Conclusion

The current study proposed that serum miR-1181 and miR-4314 could discriminate the EOC patients from healthy controls. In addition, both miR-1181 and miR-4314 may be predictive biomarkers for ovarian cancer prognosis. Further studies are needed to confirm the findings of the present study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to restrictions e.g. their containing information that could compromise the privacy of research participants.

References

  1. Minareci Y et al (2022) Prolongation of neoadjuvant chemotherapy before surgery: seeking the optimal number of cycles in Serous Ovarian Cancer. Chemotherapy 67(1):1–11

    Article  CAS  PubMed  Google Scholar 

  2. Doubeni CA, Doubeni AR, Myers AE (2016) Diagnosis and management of Ovarian Cancer. Am Fam Physician 93(11):937–944

    PubMed  Google Scholar 

  3. Elias KM, Guo J, Bast RC Jr. (2018) Early detection of Ovarian Cancer. Hematol Oncol Clin North Am 32(6):903–914

    Article  PubMed  PubMed Central  Google Scholar 

  4. Zhao L et al (2022) The role of miRNA in Ovarian Cancer: an overview. Reprod Sci 29(10):2760–2767

    Article  CAS  PubMed  Google Scholar 

  5. Song Z et al (2019) MicroRNA-1181 supports the growth of hepatocellular carcinoma by repressing AXIN1. Biomed Pharmacother 119:109397

    Article  CAS  PubMed  Google Scholar 

  6. Kafshdooz L et al (2018) The role of microRNAs and nanoparticles in ovarian cancer: a review. Artif Cells Nanomed Biotechnol 46(sup2):241–247

    Article  CAS  PubMed  Google Scholar 

  7. Zhang HY et al (2015) Activation of ARK5/miR-1181/HOXA10 axis promotes epithelial-mesenchymal transition in ovarian cancer. Oncol Rep 34(3):1193–1202

    Article  PubMed  Google Scholar 

  8. Ruan L et al (2018) Serum miR-1181 and miR-4314 associated with ovarian cancer: MiRNA microarray data analysis for a pilot study. Eur J Obstet Gynecol Reprod Biol 222:31–38

    Article  CAS  PubMed  Google Scholar 

  9. Weber JA et al (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56(11):1733–1741

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Xiao YF et al (2013) microRNA detection in feces, sputum, pleural effusion and urine: novel tools for cancer screening (review). Oncol Rep 30(2):535–544

    Article  CAS  PubMed  Google Scholar 

  11. Mishra S, Yadav T, Rani V (2016) Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol 98:12–23

    Article  PubMed  Google Scholar 

  12. Wang W et al (2022) Integrated analysis of ascites and plasma extracellular vesicles identifies a miRNA-based diagnostic signature in ovarian cancer. Cancer Lett 542:215735

    Article  CAS  PubMed  Google Scholar 

  13. Zavesky L et al (2015) Evaluation of cell-free urine microRNAs expression for the use in diagnosis of ovarian and endometrial cancers. A pilot study. Pathol Oncol Res 21(4):1027–1035

    Article  CAS  PubMed  Google Scholar 

  14. Fukagawa S et al (2017) MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer. Cancer Sci 108(5):886–896

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kim S et al (2019) Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas. J Cancer 10(9):1958–1967

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Shi M et al (2018) MicroRNA-200 and microRNA-30 family as prognostic molecular signatures in ovarian cancer: a meta-analysis. Med (Baltim) 97(32):e11505

    Article  CAS  Google Scholar 

  17. Zhu T et al (2017) A pilot study of circulating MicroRNA-125b as a diagnostic and prognostic biomarker for epithelial ovarian Cancer. Int J Gynecol Cancer 27(1):3–10

    Article  PubMed  Google Scholar 

  18. Wang W et al (2019) Five serum microRNAs for detection and predicting of ovarian cancer. Eur J Obstet Gynecol Reprod Biol X 3:100017

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kminkova J et al (2014) Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemia. Carcinogenesis 35(5):992–1002

    Article  CAS  PubMed  Google Scholar 

  20. Adam-Artigues A et al (2021) Identification of a Two-MicroRNA signature in plasma as a Novel Biomarker for very early diagnosis of breast Cancer. Cancers (Basel), 13(11)

  21. Dyba T et al (2021) The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer 157:308–347

    Article  PubMed  PubMed Central  Google Scholar 

  22. Siegel RL et al (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17–48

    Article  PubMed  Google Scholar 

  23. Webb PM, Jordan SJ (2017) Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 41:3–14

    Article  PubMed  Google Scholar 

  24. Peres LC et al (2019) Invasive epithelial ovarian Cancer survival by Histotype and Disease Stage. J Natl Cancer Inst 111(1):60–68

    Article  PubMed  Google Scholar 

  25. Fortner RT et al (2023) Characterization of ovarian cancer survival by histotype and stage: a nationwide study in Norway. Int J Cancer 153(5):969–978

    Article  CAS  PubMed  Google Scholar 

  26. Matz M et al (2017) Worldwide comparison of ovarian cancer survival: histological group and stage at diagnosis (CONCORD-2). Gynecol Oncol 144(2):396–404

    Article  PubMed  Google Scholar 

  27. Davidson B, Trope CG, Reich R (2014) The clinical and diagnostic role of microRNAs in ovarian carcinoma. Gynecol Oncol 133(3):640–646

    Article  CAS  PubMed  Google Scholar 

  28. Di Leva G et al (2013) Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet 9(3):e1003311

    Article  PubMed  PubMed Central  Google Scholar 

  29. Peter ME (2010) Targeting of mRNAs by multiple miRNAs: the next step. Oncogene 29(15):2161–2164

    Article  CAS  PubMed  Google Scholar 

  30. Saito T, Saetrom P (2010) MicroRNAs–targeting and target prediction. N Biotechnol 27(3):243–249

    Article  CAS  PubMed  Google Scholar 

  31. Cai H et al (2013) Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Med Oncol 30(1):452

    Article  PubMed  Google Scholar 

  32. Shao C et al (2019) The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis. BMC Cancer 19(1):1103

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Liu F et al (2021) Prognostic value of miR-1181 in non-small cell lung cancer and its regulatory effect on tumor progression. Exp Ther Med 22(5):1284

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Hua X, Fan KC (2019) Down-regulation of miR-1181 indicates a dismal prognosis for nasopharyngeal carcinoma and promoted cell proliferation and metastasis by modulating Wnt/beta-catenin signaling. Eur Rev Med Pharmacol Sci 23(3):1077–1086

    CAS  PubMed  Google Scholar 

  35. Jiang J et al (2015) MiR-1181 inhibits stem cell-like phenotypes and suppresses SOX2 and STAT3 in human pancreatic cancer. Cancer Lett, 356(2 Pt B): p. 962–970

  36. Wang J et al (2017) miR-1181 inhibits invasion and proliferation via STAT3 in pancreatic cancer. World J Gastroenterol 23(9):1594–1601

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. He B et al (2020) miRNA-based biomarkers, therapies, and resistance in Cancer. Int J Biol Sci 16(14):2628–2647

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Hill M, Tran N (2021) miRNA interplay: mechanisms and consequences in cancer. Dis Model Mech, 14(4)

  39. Oom AL, Humphries BA, Yang C (2014) MicroRNAs: novel players in cancer diagnosis and therapies. Biomed Res Int 2014:p959461

    Article  Google Scholar 

  40. Gao YC, Wu J (2015) MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer. Tumour Biol 36(6):4843–4850

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This research was supported by the Scientific Research Project Unit of Istanbul University (Project number: TSA-2019-35361). No other specific grant was received from any funding agency in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Faculty of Medicine, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Istanbul University, Istanbul, Turkey

    Yagmur Minareci, Hamdullah Sozen, M. Yavuz Salihoglu & Samet Topuz

  2. Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey

    Naziye Ak

  3. Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Goztepe Research and Education Hospital, Istanbul Medeniyet University, Istanbul, Turkey

    Ozgur A. Tosun

  4. Faculty of Medicine, Department of Biochemistry, Istanbul University, Istanbul, Turkey

    Canan Kucukgergin, Fatih Aydin & İlknur Bingul

Authors
  1. Yagmur Minareci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naziye Ak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hamdullah Sozen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ozgur A. Tosun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Canan Kucukgergin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fatih Aydin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. İlknur Bingul
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Yavuz Salihoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Samet Topuz
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Y. Minareci: Project development, data collection, data analysis, manuscript writing and editingN. Ak: Project development, data analysis, manuscript editingH. Sozen: Project development, supervisionO. A. Tosun: Data collectionC. Kucukgergin: Project development, data management, manuscript editingA. F. Aydin: Project development, data management, manuscript editing, İ. Bingul: Data management, M.Y. Salihoglu: Project development, supervision S. Topuz: Project development, supervision.

Corresponding author

Correspondence to Yagmur Minareci.

Ethics declarations

Ethical approval

The instutional review board and ethics committee of Istanbul University approved our study protocol (ethics number: 1119, date: 08/2019).

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Minareci, Y., Ak, N., Sozen, H. et al. The evaluation of miR-1181 and miR-4314 as serum microRNA biomarkers for epithelial ovarian cancer diagnosis and prognosis. Mol Biol Rep 51, 515 (2024). https://doi.org/10.1007/s11033-024-09464-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11033-024-09464-y

Keywords

Search

Navigation